Kiromic BioPharma, Inc. (KRBP) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Kiromic BioPharma, Inc. (KRBP) Bundle
Evaluate Kiromic BioPharma, Inc. (KRBP) financial outlook like an expert! This (KRBP) DCF Calculator provides pre-filled financials along with the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your predictions.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -3.6 | -19.0 | -25.7 | -32.5 | -16.3 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .1 | .2 | .5 | 2.1 | 2.8 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -3.7 | -19.2 | -26.2 | -34.6 | -19.1 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 1.9 | 10.2 | 25.4 | .6 | 3.2 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .5 | .7 | 2.2 | 7.3 | 2.1 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -.3 | -1.5 | -1.9 | -4.9 | -.2 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | -1.65 | -1.65 | -1.65 | -1.65 | -1.65 | -1.65 | -1.65 | -1.65 | -1.65 | -1.65 |
EBITAT | -3.7 | -19.2 | -26.3 | -38.0 | -19.4 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -3.5 | -20.2 | -26.2 | -35.7 | -22.0 | -2.1 | .0 | .0 | .0 | .0 |
WACC, % | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.0 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | 12 | |||||||||
Equity Value | -14 | |||||||||
Diluted Shares Outstanding, MM | 1 | |||||||||
Equity Value Per Share | -13.09 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real KRBP financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effects of your inputs on Kiromic BioPharma's valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Data: Kiromic BioPharma's (KRBP) historical financial reports and projected forecasts included.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Calculations: Instantly view the intrinsic value of Kiromic BioPharma (KRBP) as it updates live.
- Intuitive Visualizations: Dashboard graphs present valuation outcomes and essential metrics clearly.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file containing Kiromic BioPharma's (KRBP) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and analyze outcomes instantly.
- Make Decisions: Leverage the valuation results to inform your investment strategy.
Why Choose Kiromic BioPharma's Calculator?
- Precision: Utilizes real Kiromic BioPharma financials for reliable data accuracy.
- Adaptability: Built to allow users to easily test and adjust inputs as needed.
- Efficiency: Eliminate the complexity of constructing a DCF model from the ground up.
- Expert-Level: Crafted with the precision and usability expected by CFOs.
- Intuitive: Designed for ease of use, even for those without extensive financial modeling skills.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for assessing investment opportunities in Kiromic BioPharma, Inc. (KRBP).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Offer clients precise valuation insights for Kiromic BioPharma, Inc. (KRBP) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech companies like Kiromic BioPharma, Inc. (KRBP) are valued in the marketplace.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Kiromic BioPharma historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Kiromic BioPharma, Inc. (KRBP).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.